Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for ser... Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Alkermes is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Alkermes is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Alkermes's data?

Start your 30-day free trial to request a data review for Alkermes.

Start Free Trial

Legal Center Contact Us

Alkermes Plc

Alkermes is not subject to EU Taxonomy reporting

Account Restricted